Lilly launches new diabetes product

The new formula, which comprises 50% insulin lispro protamine suspension and 50% insulin lispro injection (rDNA origin), is now available in an easy-to-use pen delivery device in the US.

Humalog Mix50/50 is designed to provide blood sugar control between meals but also includes a higher percentage of rapid-acting insulin for people with diabetes who need more insulin control at mealtime. The Humalog component starts lowering blood sugar more quickly than regular human insulin, allowing for convenient dosing immediately before a meal.

“Some people with diabetes try to make an effort but are busy and don’t always eat balanced meals. For those who need improved blood sugar control at mealtime while also balancing their blood sugar between meals, Humalog Mix50/50 may provide a new solution,” said Ron Hoven, diabetes care marketing director, Eli Lilly.

This isn’t Lilly’s only new diabetes product; the company is also experiencing success with the recently launched Byetta. The treatment, which has been on the market for less than a year, has already been selling well for Lilly and its partner Amylin Pharmaceuticals, with analysts suggesting it could be a multibillion-dollar blockbuster for the companies.